NEW YORK, Aug. 23 – Eli Lilly and Co. said it plans to acquire a 9 percent stake in Isis Pharmaceuticals in a $200 million, four-year deal in which it will license an antisense cancer compound being developed by Isis, and collaborate to use Isis' antisense technology to discover new drugs, the companies said.

Under the terms of the partnership, Lilly will pay $75 million, or $18 a share, for its stake in Isis, as well as $25 million to license ISIS 3521, the company’s promising antisense candidate for lung cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.